The JPH1 antibody targets junctophilin-1 (JPH1), a member of the junctophilin family critical for maintaining structural and functional coupling between plasma membrane voltage-gated Ca²⁺ channels and intracellular ryanodine receptors in excitable cells. Predominantly expressed in neurons and pancreatic β-cells, JPH1 facilitates precise regulation of Ca²⁺ signaling, which is essential for neurotransmitter release, insulin secretion, and cellular excitability. Its role in stabilizing endoplasmic reticulum-plasma membrane junctions has drawn attention in neurobiology and metabolic research.
JPH1 antibodies are widely used to investigate molecular mechanisms underlying neurological disorders, diabetes, and cardiovascular diseases. Studies link JPH1 dysfunction to disrupted Ca²⁺ homeostasis, potentially contributing to pathologies like Alzheimer’s disease, arrhythmias, and impaired glucose metabolism. These antibodies enable detection of JPH1 expression levels, cellular localization, and interaction partners via techniques such as Western blotting, immunohistochemistry, and co-immunoprecipitation. Recent research also explores JPH1’s involvement in cancer progression, where altered Ca²⁺ dynamics may influence tumor cell proliferation and apoptosis. Despite its significance, JPH1’s isoform-specific functions and regulatory pathways remain incompletely understood, necessitating further studies using validated antibodies to unravel its therapeutic potential. Commercial JPH1 antibodies are typically raised against conserved epitopes, with validation emphasizing specificity across human and model organism samples.